NHG-Standaard
M92
1.1
februari 2010
februari 2010
L. Bewegingsapparaat
Richtlijnen diagnostiek
Naar Volledige tekst ›Anamnese
Naar Volledige tekst ›Lichamelijk onderzoek
Naar Volledige tekst ›Aanvullend onderzoek
Naar Volledige tekst ›Evaluatie
Naar Volledige tekst ›Richtlijnen beleid
Naar Volledige tekst ›Voorlichting
Naar Volledige tekst ›Medicamenteuze behandeling
Naar Volledige tekst ›Controles
Naar Volledige tekst ›Kernboodschappen
Naar Samenvatting ›Achtergronden
Naar Samenvatting ›Polymyalgia rheumatica
Naar Samenvatting ›Kenmerken
Naar Samenvatting ›Epidemiologie
Naar Samenvatting ›Klachten en symptomen
Naar Samenvatting ›Prognose
Naar Samenvatting ›Arteriitis temporalis
Naar Samenvatting ›Kenmerken
Naar Samenvatting ›Epidemiologie
Naar Samenvatting ›Klachten en symptomen
Naar Samenvatting ›Prognose
Naar Samenvatting ›Richtlijnen diagnostiek
Naar Samenvatting ›Anamnese
Naar Samenvatting ›Lichamelijk onderzoek
Naar Samenvatting ›Aanvullend onderzoek
Naar Samenvatting ›Evaluatie
Naar Samenvatting ›Richtlijnen beleid
Naar Samenvatting ›Voorlichting en advies
Naar Samenvatting ›Thuisarts
Naar Samenvatting ›Niet-medicamenteuze behandeling
Naar Samenvatting ›Medicamenteuze behandeling
Naar Samenvatting ›Polymyalgia rheumatica
Naar Samenvatting ›1e 3 maanden
Naar Samenvatting ›Na 1e 3 maanden
Naar Samenvatting ›Aandachtspunten bij behandeling met glucocorticoïden
Naar Samenvatting ›Arteriitis temporalis
Naar Samenvatting ›Controles
Naar Samenvatting ›Verwijzing of consultatie
Naar Samenvatting ›Referenties
- Bahlas S, Ramos-Remus C, Davis P. Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clin Rheumatol 2000;19: 278-80.
- Brooks RC, McGee SR. Diagnostic dilemmas in polymyalgia rheumatica. Arch Intern Med 1997;157:162-8.
- Dasgupta B, Salvarani C, Schirmer M, Crowson CS, Maradit-Kremers H, Hutchings A et al. Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008;35: 270-7.
- Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38:434-9.
- Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981;40:1-5.
- Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982;97:672-80.
- Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322-8.
- Martinez-Taboada VM, Blanco R, Rodriguez-Valverde V. Polymyalgia rheumatica with normal erythrocyte sedimentation rate: clinical aspects. Clin Exp Rheumatol 2000;18: S34-S37.
- Cantini F, Salvarani C, Olivieri I. Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica. Ann Intern Med 1998;128:873-4.
- Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.
- Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996;35:1161-8.
- Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:S9-11.
- Goodwin JS. The very low prevalence of polymyalgia rheumatica in blacks may be an artifact. J Am Geriatr Soc 1990;38:824-6.
- Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006;65:1093-8.
- Van de Lisdonk EH, Van den Bosch WJHM, Lagro-Janssen ALM. Ziekten in de huisartspraktijk. 5de editie. Maarssen: Elsevier Gezondheidszorg, 2008.
- Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998;41:1221-6.
- Ceccato F, Roverano SG, Papasidero S, Barrionuevo A, Rillo OL, Paira SO. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol 2006;12:167-71.
- Bird HA, Leeb BF, Montecucco CM, Misiuniene N, Nesher G, Pai S, et al. A comparison of the sensitivity of diagnostic criteria for polymyalgia rheumatica. Ann Rheum Dis 2005;64:626-9.
- Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27:2179-84.
- Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004;33:294-301.
- Cantini F, Niccoli L, Nannini C, Bertoni M, Salvarani C. Diagnosis and treatment of giant cell arteritis. Drugs Aging 2008;25:281-97.
- Pavlica P, Barozzi L, Salvarani C, Cantini F, Olivieri I. Magnetic resonance imaging in the diagnosis of PMR. Clin Exp Rheumatol 2000;18:S38-S39.
- Bagratuni L. Anarthritic rheumatoid disease. Lancet 1956;271:694-7.
- Bagratuni L. Prognosis in the anarthritic rheumatoid syndrome. Br Med J 1963;1:513-8.
- Barber HS. Myalgic syndrome with constitutional effects; polymyalgia rheumatica. Ann Rheum Dis 1957;16:230-7.
- Warrington KJ, Jarpa EP, Crowson CS, Cooper LT, Hunder GG, Matteson EL, et al. Increased risk of peripheral arterial disease in polymyalgia rheumatica: a population-based cohort study. Arthritis Res Ther 2009;11:R50.
- Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM, III, Hunder GG, Gabriel SE. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum 2007;57:279-86.
- Miller NR. Visual manifestations of temporal arteritis. Rheum Dis Clin North Am 2001;27:781-97, vi.
- Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993;100:550-5.
- Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005;112:1098-103.
- Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001;111:211-7.
- Stone JH. Vasculitis: a collection of pearls and myths. Rheum Dis Clin North Am 2007;33:691-739, v.
- Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990;33:1065-7.
- Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998;129:345-52.
- Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994;120:987-92.
- Barraclough K, Liddell WG, Du Toit J, Foy C, Dasgupta B, Thomas M, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract 2008;25:328-33.
- Solomon S, Cappa KG. The headache of temporal arteritis. J Am Geriatr Soc 1987;35:163-5.
- Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008;337:a2286.
- Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002;287:92-101.
- Van der Meer J, Stehouwer CDA. Interne geneeskunde. 13de editie. Houten: Bohn Stafleu van Loghum, 2005.
- Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2004;141:493-500.
- Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I. Atypical polymyalgia rheumatica as a presentation of metastatic cancer. Arch Intern Med 1997;157:2381.
- Siebert S, Lawson TM, Wheeler MH, Martin JC, Williams BD. Polymyalgia rheumatica: pitfalls in diagnosis. J R Soc Med 2001;94:242-4.
- Li C, Dasgupta B. Corticosteroids in polymyalgia rheumatica -- a review of different treatment schedules. Clin Exp Rheumatol 2000;18:S56-S57.
- Vos PAJM, Bijlsma JWJ, Derksen RHWM. Polymyalgia rheumatica en arteriitis temporalis. Ned Tijdschr Geneeskd 2005;149:1932-7.
- Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-61.
- Carmona L. Quantifying risks: the case between glucocorticoids and tuberculosis. Arthritis Rheum 2006;55:1-2.
- NICE. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (2006). Royal College of Physicians. Geraadpleegd mei 2009. Ga naar bron: NICE. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control (2006). Royal College of Physicians. Geraadpleegd mei 2009.
- Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26.
- Mulder AH, Nauta S, Pieters GF, Hermus AR. Addison-crisis bij patienten bekend wegens bijnierschorsinsufficientie: het belang van vroegtijdig ingrijpen. Ned Tijdschr Geneeskd 2008;152:1497-500.
- Hermus AR, Zelissen PM. Diagnostiek en therapie bij patienten met bijnierschorsinsufficientie. Ned Tijdschr Geneeskd 1998;142:944-9.
- Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
- Leendertse AJ, Egberts AC, Stoker LJ, Van den Bemt PM. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168:1890-6.
- Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63:1279-83.
- Binard A, De Bandt M, Berthelot JM, Saraux A. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum 2007;57:481-6.
- Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803-9.
- Kyle V, Hazleman BL. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 1993;52:847-50.
- Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005;53:33-8.
- Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 2005;32:65-73.
- Prickarts M, Lagro-Janssen T. Polymyalgia rheumatica in vier huisartspraktijken. Huisarts Wet 1999;42:597-601.
- Van der Veen MJ, Dinant HJ, Van Booma-Frankfort C, Van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 1996;55:218-23.
- Ferraccioli G, Salaffi F, De Vita S., Casatta L, Bartoli E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 1996;23:624-8.
- Caporali R, Montecucco C, Epis O, Bobbio-Pallavicini F, Maio T, Cimmino MA. Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Ann Rheum Dis 2001;60:1021-4.
- Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
- Verduijn MM, Van den Bemt BJF, Dijkmans BAC, Van der Waal RIF, Horikx A. Methotrexaat veilig, mits juist voorgeschreven. Ned Tijdschr Geneesk 2009;153:A695.